安踏體育(02020.HK)第三季度安踏品牌產品零售金額增長10-20%
格隆匯10月18日丨安踏體育(02020.HK)公佈,2021年第三季度安踏品牌產品的零售金額,與2020年同期比較錄得10-20%低段的正增長,而與2019年同期比較錄得10-20%中段的正增長。
2021年第三季度FILA品牌產品的零售金額(按零售價值計算),與2020年同期比較錄得中單位數的正增長,而與2019年同期比較錄得25-30%的正增長。
此外,2021年第三季度所有其他品牌產品的零售金額(按零售價值計算),與2020年同期比較錄得35-40%的正增長,而與2019年同期比較錄得105-110%的正增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.